Results 21 to 30 of about 9,247 (168)

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

Haematologica, 2020
Intravenous daratumumab is approved for the treatment of multiple myeloma. In Part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of ...
Jesus San-Miguel, Saad Z. Usmani, Maria-Victoria Mateos, Niels W.C.J. van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Kevin Liu, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Andrew Farnsworth, Hareth Nahi, Ajai Chari   +16 more
doaj   +1 more source

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Experimental Hematology & Oncology, 2018
Background The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells.
Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga, Raymond L. Comenzo   +13 more
doaj   +1 more source

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

Haematologica, 2020
CD38 is expressed in several types of non-Hodgkin lymphoma (NHL) and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory (R/R) multiple
Anna Vidal-Crespo, Alba Matas-Céspedes, Vanina Rodriguez, Cédric Rossi, Juan G. Valero, Neus Serrat, Alejandra Sanjuan-Pla, Pablo Menéndez, Gaël Roué, Armando López-Guillermo, Eva Giné, Elías Campo, Dolors Colomer, Christine Bezombes, Jeroen Lammerts van Bueren, Christopher Chiu, Parul Doshi, Patricia Pérez-Galán   +17 more
doaj   +1 more source

Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation

Therapeutic Advances in Hematology, 2021
Daratumumab is a humanized anti-CD38 IgG1 monoclonal antibody which could be used for multiple myeloma (MM). MM with plasma-cell leukemia (PCL) transformation is highly aggressive and is resistant to conventional therapy.
Chen-lu Yang, Neng-gang Jiang, Li Zhang, Kai Shen, Yu Wu   +4 more
doaj   +1 more source

Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis

Journal of International Medical Research, 2021
Objective To systematically evaluate the efficacy and safety of combination regimens containing daratumumab in patients with multiple myeloma (MM). Methods A systematic search of publications listed on electronic databases (PubMed®, The Cochrane Library,
Yin Wang, Yanqing Li, Ye Chai
doaj   +1 more source

Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival

Haematologica, 2023
Treatment of patients with Mayo stage IIIb light chain (AL) amyloidosis is still challenging, and the prognosis remains very poor. Mayo stage IIIb patients were excluded from the pivotal trial leading to the approval of daratumumab in combination with ...
Sara Oubari, Ute Hegenbart, Renate Schoder, Maximilian Steinhardt, Maria Papathanasiou, Tienush Rassaf, Andreas Thimm, Tim Hagenacker, Eyad Naser, Ulrich Duhrsen, Hans C. Reinhardt, Martin Kortum, Hermine Agis, Stefan Schonland, Alexander Carpinteiro   +14 more
doaj   +1 more source

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Blood Advances, 2017
: Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated clinical activity and a manageable safety profile in monotherapy and combination therapy clinical trials in relapsed and/or refractory multiple myeloma.
Tineke Casneuf, Xu Steven Xu, Homer C. Adams, III, Amy E. Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W.C.J. van de Donk, Pamela L. Clemens, A. Kate Sasser   +13 more
doaj   +1 more source

B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses

Life Science Alliance, 2023
Daratumumab is an anti-CD38–targeting antibody that depletes plasma cells. This study shows that daratumumab also disturbs humoral immune responses beyond depletion only and may be used as therapeutic in B cell–mediated autoimmune diseases.
Dorit Verhoeven, Lucas Grinwis, Casper Marsman, Machiel H Jansen, Ester MM Van Leeuwen, Taco W Kuijpers   +5 more
doaj   +1 more source

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

Hematology, Transfusion and Cell Therapy, 2021
Introduction: Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM).
Edvan de Queiroz Crusoé, Flávia Cristina Fernandes Pimenta, Angelo Maiolino, Nelson Siqueira de Castro, Huiling Pei, Damila Trufelli, Mariana Fernandez, Luciana Barreto Herriot   +7 more
doaj   +1 more source

Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

OncoImmunology, 2019
Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity
Wojciech Dawicki, Kevin J.H. Allen, Rubin Jiao, Mackenzie E. Malo, Muath Helal, Mark S. Berger, Dale L. Ludwig, Ekaterina Dadachova   +7 more
doaj   +1 more source